Skip to content

ARCIM® is our investigational spinal cord stimulation system designed to address blood pressure instability and other symptoms in people with SCI.

Meet Julie and learn about her journey

Read The Evidence

The STIMO study demonstrated the ability of this therapy to enable long-paralyzed people to stand and walk again with little or no assistance.

We received FDA Breakthrough Device Designation for ARCIM in 2020 to restore leg motor function in people with spinal cord injury. Then in 2021, for the use of the system to normalize blood pressure and provide trunk stability, in 2022 for bladder control, and in 2023 for reduced spasticity.

Other potential indications we may explore include improved sexual function and bowel control, and Parkinson’s mobility and gait.

Discover The Potential Benefits

ARCIM utilizes ARC Therapy™, which is targeted, programmed electrical stimulation of the spinal cord at the site of the injury to restore movement or a specific function.

The system consists of an implanted Neurostimulator (IPG) and an implanted epidural lead designed specifically for people with SCI.

This is a example

Blood pressure regulation

Upper and lower limb function

Bladder control

Improved Blood Pressure Regulation

ARCIM is the first neuroprosthetic system designed to reduce the symptoms related to Orthostatic and Postprandial Hypotension and Autonomic Dysreflexia (AD) in people living with chronic spinal cord injury (SCI) at lesion level C3-T6 AIS A-D.


Learn about how we are pairing brain-computer interface (BCI) technology to enhance our ARCIM platform with more natural movement after paralysis.

Contact Us

Please fill out the form
if you would like to contact
us or receive updates

All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.